<p>Serum Institute of India (SII) and Indian Council of Medical Research (ICMR), the apex body in India for biomedical research, announced completion of enrolment of phase-III clinical trials for COVISHIELD in India.</p>.<p>ICMR and SII have further collaborated for the clinical development of COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII.</p>.<p>SII CEO Adar Poonawalla said ICMR has played a huge role in coming forward and strengthening India’s fight against Covid-19. “The collaboration will further aid us in putting India at the forefront of developing an immunogenic and efficacious vaccine. The pandemic has presented a chance to foster structural reforms in building robust public healthcare infrastructure. The partnership further testifies the importance of private-public institutes coming together in scaling up the management and containing the spread of the virus,” he said.</p>.<p>ICMR Director General said that India plays a prominent role in vaccine development and manufacturing globally. “Buoyed by the latest technology and well-equipped facilities, SII has continually proven its research and manufacturing prowess. The partnership is our contribution to lending our expertise and support to bolster our fight against the global pandemic,” he said.</p>.<p>According to a press statement, ICMR has funded the clinical trial site fees while SII has funded, other expenses for COVISHIELD. At present, SII and ICMR are conducting Phase 2/3 clinical trials of COVISHIELD at 15 different centres, across the country.</p>.<p>It has completed the enrolment of all 1,600 participants on 31 Oct 2020.<br /><br /><strong>Also Read | <a href="https://www.deccanherald.com/national/should-india-forget-about-acquiring-pfizer-covid-19-vaccine-914336.html" target="_blank">Should India forget about acquiring Pfizer Covid-19 vaccine?</a></strong></p>.<p>COVISHIELD has been developed at the SII Pune laboratory with a master seed from Oxford University/AstraZeneca. The vaccine made in the UK is currently being tested in large efficacy trials in the UK, Brazil, South Africa and USA. The promising results of the trials so far give confidence that COVISHIELD could be a realistic solution to the deadly pandemic.</p>.<p>COVISHIELD is by far the most advanced vaccine in human testing in India. Based on the Phase 2/3 trial results, SII with the help of ICMR will pursue the early availability of this product for India. SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling license from DCGI.</p>.<p>Furthermore, US-based Novavax has initiated its late phase trials in South Africa and in the UK and will soon commence the same in the USA. SII has received the bulk vaccine and Matrix-M adjuvant from Novavax and will soon fill and finish them in vials. This vaccine formulated at SII (COVOVAX) will be tested in a Phase 3 trial in India and an application for the same to regulatory authorities will be made soon by ICMR and SII.</p>
<p>Serum Institute of India (SII) and Indian Council of Medical Research (ICMR), the apex body in India for biomedical research, announced completion of enrolment of phase-III clinical trials for COVISHIELD in India.</p>.<p>ICMR and SII have further collaborated for the clinical development of COVOVAX (Novavax) developed by Novavax, USA and upscaled by SII.</p>.<p>SII CEO Adar Poonawalla said ICMR has played a huge role in coming forward and strengthening India’s fight against Covid-19. “The collaboration will further aid us in putting India at the forefront of developing an immunogenic and efficacious vaccine. The pandemic has presented a chance to foster structural reforms in building robust public healthcare infrastructure. The partnership further testifies the importance of private-public institutes coming together in scaling up the management and containing the spread of the virus,” he said.</p>.<p>ICMR Director General said that India plays a prominent role in vaccine development and manufacturing globally. “Buoyed by the latest technology and well-equipped facilities, SII has continually proven its research and manufacturing prowess. The partnership is our contribution to lending our expertise and support to bolster our fight against the global pandemic,” he said.</p>.<p>According to a press statement, ICMR has funded the clinical trial site fees while SII has funded, other expenses for COVISHIELD. At present, SII and ICMR are conducting Phase 2/3 clinical trials of COVISHIELD at 15 different centres, across the country.</p>.<p>It has completed the enrolment of all 1,600 participants on 31 Oct 2020.<br /><br /><strong>Also Read | <a href="https://www.deccanherald.com/national/should-india-forget-about-acquiring-pfizer-covid-19-vaccine-914336.html" target="_blank">Should India forget about acquiring Pfizer Covid-19 vaccine?</a></strong></p>.<p>COVISHIELD has been developed at the SII Pune laboratory with a master seed from Oxford University/AstraZeneca. The vaccine made in the UK is currently being tested in large efficacy trials in the UK, Brazil, South Africa and USA. The promising results of the trials so far give confidence that COVISHIELD could be a realistic solution to the deadly pandemic.</p>.<p>COVISHIELD is by far the most advanced vaccine in human testing in India. Based on the Phase 2/3 trial results, SII with the help of ICMR will pursue the early availability of this product for India. SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling license from DCGI.</p>.<p>Furthermore, US-based Novavax has initiated its late phase trials in South Africa and in the UK and will soon commence the same in the USA. SII has received the bulk vaccine and Matrix-M adjuvant from Novavax and will soon fill and finish them in vials. This vaccine formulated at SII (COVOVAX) will be tested in a Phase 3 trial in India and an application for the same to regulatory authorities will be made soon by ICMR and SII.</p>
